MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today the initiation of a clinical trial of its telomerase inhibitor drug, GRN163L, in patients with advanced non-small cell lung cancer (NSCLC). The primary objective of the Phase I/II study is to determine the safety and maximum tolerated dose of GRN163L when administered intravenously in combination with a standard paclitaxel/carboplatin regimen. This is the first time GRN163L is being clinically tested in combination with standard chemotherapy.
